New vaccine against Respiratory Syncytial Virus (RSV) elicits strong immune response

An experimental vaccine against respiratory syncytial virus (RSV), one of the leading causes of infectious disease deaths in infants, has shown early promise in a Phase 1 human clinical trial. Researchers report that one dose of their vaccine candidate elicited large increases in RSV-neutralizing antibodies that were sustained for several months.